Category: 3934-20-1

In 2022,Singh, Vishal K.; Chaurasia, Himani; Mishra, Richa; Srivastava, Ritika; Naaz, Farha; Kumar, Pradeep; Singh, Ramendra K. published an article in Journal of Molecular Structure. The title of the article was 《Docking, ADMET prediction, DFT analysis, synthesis, cytotoxicity, antibacterial screening and QSAR analysis of diarylpyrimidine derivatives》.Synthetic Route of C4H2Cl2N2 The author mentioned the following in the article:

A new series of 2, 4 disubstituted diarylpyrimidine derivatives has been designed, synthesized and screened for their antibacterial activity. QSAR studies followed by antibacterial screening using broth dilution technique showed excellent MIC values against four human pathogens, namely Escherichia coli, Pseudomonas aeruginosa, Bacillus cerus and Staphylococcus aureus. Some mols. were found to be highly active (MIC value up to 3.1 μg/mL) against different types of human pathogens, like P. aeruginosa, E. coli, S. aureus and B. cerus. All compounds having MIC values greater than reference drugs were subjected for combinatorial antibacterial screening with chloramphenicol, cycloheximide and paromomycin as standard references and fractional inhibitory concentration (FIC) values of compounds exhibited great synergistic effect as their MIC values were lowered by 1/33, 1/16 and 1/8 of the original MIC′s. In vitro evaluation of cytotoxicity indicates that these mols. were less toxic against HEK293 (Human embryonic kidney) cell lines. Mol. docking assessment also revealed that all designed 2,4 disubstituted diarylpyrimidine derivatives showed good interaction within active site of PDF enzyme (PDB ID: 1G2A). 2, 4 disubstituted diarylpyrimidines formed H-bond with amino acid residue Leu91, Arg97, Ile44, Ile94, Gly89 and Glu95 at a distance of 2.78 – 3.20 Å. Mols. also showed π – + and π – π interaction with amino acid residues Arg97 and His132. In silico assessment of all mols. exhibited more than 88% of intestinal absorption, which was higher than the reference antibiotics viz. chloramphenicol (69.94%), cycloheximide (74.26%) and paromomycin (76.46%). In the experiment, the researchers used many compounds, for example, 2,4-Dichloropyrimidine(cas: 3934-20-1Synthetic Route of C4H2Cl2N2)

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Organic chloride content in crude oil can be detected through specialized laboratory analysis. Care and attention are essential while sampling and testing.Synthetic Route of C4H2Cl2N2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Liu, Ju; Wu, Shuang; Wang, Huan; Du, Si-Yuan; Li, Zhen; Shen, Ji-Wei; Chen, Ye; Ding, Shi published an article in 2022. The article was titled 《Novel 2,4-diarylaminopyrimidine derivatives containing pyridine moiety: design, synthesis, crystal structure and biological evaluation》, and you may find the article in Chinese Journal of Structural Chemistry.Electric Literature of C4H2Cl2N2 The information in the text is summarized as follows:

A series of 2,4-diarylaminopyrimidine derivatives I [R = H, 4-Me, 4-F, etc.] containing pyridine structure were designed and synthesized. The crystal structures of compounds I [R = 3-Cl, 4-F-3-Cl] were obtained from X-ray diffraction. The crystal structure of I [R = 3-Cl] (C25H20ClFN6O2) belongs to the monoclinic system, space group P21/c with a = 11.0500(10), b = 18.3045(17), c = 13.5646(9) Å and β = 122.806(5)°. I [R = 4-F-3-Cl] (C25H19ClF2N6O2) was of monoclinic system, space group P21/c with a = 10.9998(18), b = 18.517(3), c = 13.6355(16) Å and β = 123.315(9)°. The bioassay results showed all of the target compounds I exhibited potential antiproliferative activities against MKN-45, HT-29, A549, K562 and GIST882 cell lines. Among them, compounds I [R = H, 4-Cl, 4-F-3-Cl] exhibited remarkable inhibitory activities against GIST882, K562 and A549 cell lines with IC50 values of 0.68, 0.38 and 0.60μM, resp., which were comparable to that of the pos. control foretinib. The results came from multiple reactions, including the reaction of 2,4-Dichloropyrimidine(cas: 3934-20-1Electric Literature of C4H2Cl2N2)

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Almost all organochlorine compounds are synthesized. It is widely used as intermediates, solvents and pesticides of chemical synthetic products.Electric Literature of C4H2Cl2N2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Recommanded Product: 3934-20-1In 2021 ,《Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2》 was published in Journal of Medicinal Chemistry. The article was written by Heightman, Tom D.; Berdini, Valerio; Bevan, Luke; Buck, Ildiko M.; Carr, Maria G.; Courtin, Aurelie; Coyle, Joseph E.; Day, James E. H.; East, Charlotte; Fazal, Lynsey; Griffiths-Jones, Charlotte M.; Howard, Steven; Kucia-Tran, Justyna; Martins, Vanessa; Muench, Sandra; Munck, Joanne M.; Norton, David; O’Reilly, Marc; Palmer, Nicholas; Pathuri, Puja; Peakman, Torren M.; Reader, Michael; Rees, David C.; Rich, Sharna J.; Shah, Alpesh; Wallis, Nicola G.; Walton, Hugh; Wilsher, Nicola E.; Woolford, Alison J.-A.; Cooke, Michael; Cousin, David; Onions, Stuart; Shannon, Jonathan; Watts, John; Murray, Christopher W.. The article contains the following contents:

Aberrant activation of the mitogen-activated protein kinase pathway frequently drives tumor growth, and the ERK1/2 kinases are positioned at a key node in this pathway, making them important targets for therapeutic intervention. Recently, a number of ERK1/2 inhibitors have been advanced to investigational clin. trials in patients with activating mutations in B-Raf proto-oncogene or Ras. Here, we describe the discovery of the clin. candidate ASTX029 (15)(I) through structure-guided optimization of our previously published isoindolinone lead (7). The medicinal chem. campaign focused on addressing CYP3A4-mediated metabolism and maintaining favorable physicochem. properties. These efforts led to the identification of ASTX029, which showed the desired pharmacol. profile combining ERK1/2 inhibition with suppression of phospho-ERK1/2 (pERK) levels, and in addition, it possesses suitable preclin. pharmacokinetic properties predictive of once daily dosing in humans. ASTX029 is currently in a phase I-II clin. trial in patients with advanced solid tumors. In the experimental materials used by the author, we found 2,4-Dichloropyrimidine(cas: 3934-20-1Recommanded Product: 3934-20-1)

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Organic chlorides are compounds containing a carbon-chlorine bond, which are widely used in the oil field as a wax dissolver. They are generally not present in crude oils and are typically the result of additives, cleaning solutions or chemicals used for oil recovery.Recommanded Product: 3934-20-1

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

In 2022,Hopkins, Brian T.; Bame, Eris; Bajrami, Bekim; Black, Cheryl; Bohnert, Tonika; Boiselle, Carrie; Burdette, Doug; Burns, Jeremy C.; Delva, Luisette; Donaldson, Douglas; Grater, Richard; Gu, Chungang; Hoemberger, Marc; Johnson, Josh; Kapadnis, Sudarshan; King, Kris; Lulla, Mukesh; Ma, Bin; Marx, Isaac; Magee, Tom; Meissner, Robert; Metrick, Claire M.; Mingueneau, Michael; Murugan, Paramasivam; Otipoby, Kevin L.; Polack, Evelyne; Poreci, Urjana; Prince, Robin; Roach, Allie M.; Rowbottom, Chris; Santoro, Joseph C.; Schroeder, Patricia; Tang, Hao; Tien, Eric; Zhang, Fengmei; Lyssikatos, Joseph published an article in Journal of Medicinal Chemistry. The title of the article was 《Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis》.Application In Synthesis of 2,4-Dichloropyrimidine The author mentioned the following in the article:

Multiple Sclerosis is a chronic autoimmune neurodegenerative disorder of the central nervous system (CNS) that is characterized by inflammation, demyelination, and axonal injury leading to permeant disability. In the early stage of MS, inflammation is the primary driver of the disease progression. There remains an unmet need to develop high efficacy therapies with superior safety profiles to prevent the inflammation processes leading to disability. Herein, we describe the discovery of BIIB091 (I), a structurally distinct orthosteric ATP competitive, reversible inhibitor that binds the BTK protein in a DFG-in confirmation designed to sequester Tyr-551, an important phosphorylation site on BTK, into an inactive conformation with excellent affinity. Preclin. studies demonstrated BIB091 to be a high potency mol. with good drug-like properties and a safety/tolerability profile suitable for clin. development as a highly selective, reversible BTKi for treating autoimmune diseases such as MS. In the experiment, the researchers used 2,4-Dichloropyrimidine(cas: 3934-20-1Application In Synthesis of 2,4-Dichloropyrimidine)

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Almost all organochlorine compounds are synthesized. It is widely used as intermediates, solvents and pesticides of chemical synthetic products.Application In Synthesis of 2,4-Dichloropyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Feng, Da; Zuo, Xiaofang; Jing, Lanlan; Chen, Chin-Ho; Olotu, Fisayo A.; Lin, Hao; Soliman, Mahmoud; De Clercq, Erik; Pannecouque, Christophe; Lee, Kuo-Hsiung; Kang, Dongwei; Liu, Xinyong; Zhan, Peng published their research in European Journal of Medicinal Chemistry in 2021. The article was titled 《Design, synthesis, and evaluation of “”dual-site””-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase》.Product Details of 3934-20-1 The article contains the following contents:

To improve the drug-resistance profiles of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs), a novel series of “”dual-site”” binding diarylpyrimidine (DAPY) derivatives I [R1 = H, cyclopropyl, propargyl, etc.] and II [X = 1-R2-piperidin-4-yl, 1-R2-piperidin-4-ylmethyl, 1-R2-pyrrolidin-3-yl; R2 = methylsulfonyl, trifluoromethylsulfonyl, trifluoromethylcarbonyl, etc.] targeting both the NNRTI adjacent site and NNRTIs binding pocket (NNIBP) were designed, synthesized and evaluated for their anti-HIV potency in TZM-bl and MT-4 cells. Eight compounds I and II exhibited moderate to excellent potencies in inhibiting wild-type (WT) HIV-1 replication with EC50 values ranging from 2.45 nM to 5.36 nM, and I [R1 = propargylamino] (EC50 = 2.45 nM) proved to be the most promising inhibitor. Of note, I [R1 = propargylamino] exhibited potent activity against the single mutant strain E138K (EC50 = 10.6 nM), being comparable with ETR (EC50 = 9.80 nM) and 3.5-fold more potent than that of morpholino pyrimidine compound (EC50 = 37.3 nM). Moreover, I [R1 = propargylamino] acted as a classical NNRTI with high affinity for WT HIV-1 RT (IC50 = 0.0589μM). The detailed structure-activity relationships (SARs) of the representative compounds were also determined, and further supported by mol. dynamics simulation. Overall, the “”dual-site””-binding NNRTIs have significant prospects and pave the way for the next round of rational design of potent anti-HIV-1 agents. In the experiment, the researchers used 2,4-Dichloropyrimidine(cas: 3934-20-1Product Details of 3934-20-1)

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Organic chloride content in crude oil can be detected through specialized laboratory analysis. Care and attention are essential while sampling and testing.Product Details of 3934-20-1

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

In 2019,Journal of Organic Chemistry included an article by Bhujabal, Yuvraj B.; Vadagaonkar, Kamlesh S.; Gholap, Aniket; Sanghvi, Yogesh S.; Dandela, Rambabu; Kapdi, Anant R.. Computed Properties of C4H2Cl2N2. The article was titled 《HFIP Promoted Low Temperature SNAr of Chloroheteroarenes Using Thiols and Amines》. The information in the text is summarized as follows:

A highly efficient and an unprecedented HFIP promoted low temperature aromatic nucleophilic substitutions of chloroheteroarenes has been performed using thiols and (secondary) amines under base-free and metal-free conditions. The developed protocol also provides excellent regio-control for the selective functionalization of dichloroheteroarenes, while the utility of the protocol was demonstrated by the modification of a com. available drug Ceritinib. In the part of experimental materials, we found many familiar compounds, such as 2,4-Dichloropyrimidine(cas: 3934-20-1Computed Properties of C4H2Cl2N2)

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Almost all organochlorine compounds are synthesized. It is widely used as intermediates, solvents and pesticides of chemical synthetic products.Computed Properties of C4H2Cl2N2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

In 2022,Yuan, Kai; Kuang, Wenbin; Chen, Weijiao; Ji, Minghui; Min, Wenjian; Zhu, Yasheng; Hou, Yi; Wang, Xiao; Li, Jiaxing; Wang, Liping; Yang, Peng published an article in European Journal of Medicinal Chemistry. The title of the article was 《Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma》.Application of 3934-20-1 The author mentioned the following in the article:

Multiple myeloma (MM) ranks second in malignant hematopoietic cancers, and the most common anti-MM drugs easily generate resistance. CDK4/6 have been validated to play determinant roles in MM, but no remarkable progress has been obtained from clin. trials of CDK4/6 inhibitors for MM. To discover novel CDK6 inhibitors with better potency and high druggability, structure-based virtual screening was conducted to identify compound I. Further chem. optimization afforded a better derivative, compound II, which exhibited strong inhibition of CDK4/6 and showed high selectivity over 360+ kinases, including homologous CDKs. The in vivo evaluation demonstrated that compound II possessed low toxicity (LD50 > 10,000 mg/kg), favorable bioavailability (F% = 51%), high metabolic stability (t1/2 > 24 h) and strong anti-MM potency. In summary, we discovered a novel CDK4/6 inhibitor bearing favorable drug-like properties and offered a great candidate for MM preclin. studies. The experimental part of the paper was very detailed, including the reaction process of 2,4-Dichloropyrimidine(cas: 3934-20-1Application of 3934-20-1)

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Almost all organochlorine compounds are synthesized. It is widely used as intermediates, solvents and pesticides of chemical synthetic products.Application of 3934-20-1

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Yang, Fan; Su, Huilin; Deng, Ji; Mou, Luohe; Wang, Huali; Li, Rong; Dai, Qing-Qing; Yan, Yu-Hang; Qian, Shan; Wang, Zhouyu; Li, Guo-Bo; Yang, Lingling published an article in 2021. The article was titled 《Discovery of new human Sirtuin 5 inhibitors by mimicking glutaryl-lysine substrates》, and you may find the article in European Journal of Medicinal Chemistry.COA of Formula: C4H2Cl2N2 The information in the text is summarized as follows:

Human sirtuin 5 (SIRT5) plays pivotal roles in metabolic pathways and other biol. processes, and is involved in several human diseases including cancer. Development of new potent and selective SIRT5 inhibitors is currently desirable to provide potential therapeutics for related diseases. Herein, we report a series of new 3-thioureidopropanoic acid derivatives, which were designed to mimic the binding features of SIRT5 glutaryl-lysine substrates. Structure-activity relationship studies revealed several compounds with low micromolar inhibitory activities to SIRT5. Computational and biochem. studies indicated that these compounds exhibited competitive SIRT5 inhibition with respect to the glutaryl-lysine substrate rather than NAD cofactor. Moreover, they showed high selectivity for SIRT5 over SIRT1-3 and 6 and could stabilize SIRT5 proteins as revealed by thermal shift analyses. This work provides an effective substrate-mimicking strategy for future inhibitor design, and offers new inhibitors to investigate their therapeutic potentials in SIRT5-associated disease models. After reading the article, we found that the author used 2,4-Dichloropyrimidine(cas: 3934-20-1COA of Formula: C4H2Cl2N2)

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Organic chloride content in crude oil can be detected through specialized laboratory analysis. Care and attention are essential while sampling and testing.COA of Formula: C4H2Cl2N2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Al-Khawaldeh, Islam; Al Yasiri, Mohammed J.; Aldred, Gregory G.; Basmadjian, Christine; Bordoni, Cinzia; Harnor, Suzannah J.; Heptinstall, Amy B.; Hobson, Stephen J.; Jennings, Claire E.; Khalifa, Shaimaa; Lebraud, Honorine; Martin, Mathew P.; Miller, Duncan C.; Shrives, Harry J.; de Souza, Joao V.; Stewart, Hannah L.; Temple, Max; Thomas, Huw D.; Totobenazara, Jane; Tucker, Julie A.; Tudhope, Susan J.; Wang, Lan Z.; Bronowska, Agnieszka K.; Cano, Celine; Endicott, Jane A.; Golding, Bernard T.; Hardcastle, Ian R.; Hickson, Ian; Wedge, Stephen R.; Willmore, Elaine; Noble, Martin E. M.; Waring, Michael J. published their research in Journal of Medicinal Chemistry in 2021. The article was titled 《An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase》.Computed Properties of C4H2Cl2N2 The article contains the following contents:

NF-κB-inducing kinase (NIK) is a key enzyme in the noncanonical NF-κB pathway, of interest in the treatment of a variety of diseases including cancer. Validation of NIK as a drug target requires potent and selective inhibitors. The protein contains a cysteine residue at position 444 in the back pocket of the active site, unique within the kinome. Anal. of existing inhibitor scaffolds and early structure-activity relationships (SARs) led to the design of C444-targeting covalent inhibitors based on alkynyl heterocycle warheads. Mass spectrometry provided proof of the covalent mechanism, and the SAR was rationalized by computational modeling. Profiling of more potent analogs in tumor cell lines with constitutively activated NIK signaling induced a weak antiproliferative effect, suggesting that kinase inhibition may have limited impact on cancer cell growth. This study shows that alkynyl heterocycles are potential cysteine traps, which may be employed where common Michael acceptors, such as acrylamides, are not tolerated. In the experiment, the researchers used many compounds, for example, 2,4-Dichloropyrimidine(cas: 3934-20-1Computed Properties of C4H2Cl2N2)

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Almost all organochlorine compounds are synthesized. It is widely used as intermediates, solvents and pesticides of chemical synthetic products.Computed Properties of C4H2Cl2N2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

《Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities》 was written by Xiao, Ting; Tang, Jia-Fan; Meng, Ge; Pannecouque, Christophe; Zhu, Yuan-Yuan; Liu, Gen-Yan; Xu, Zhi-Qiang; Wu, Feng-Shou; Gu, Shuang-Xi; Chen, Fen-Er. Recommanded Product: 3934-20-1 And the article was included in European Journal of Medicinal Chemistry in 2020. The article conveys some information:

A series of indazolyl-substituted piperidin-4-yl-aminopyrimidines (IPAPYs) I (R = 2-Cl, 2-Br, 2-CF3, etc.) were designed from two potent HIV-1 NNRTIs piperidin-4-yl-aminopyrimidine and diaryl ether as the lead compounds by mol. hybridization strategy. The target mols. I were synthesized and evaluated for their anti-HIV activities and cytotoxicities in MT-4 cells. I displayed moderate to excellent activities against wild-type (WT) HIV-1 with EC50 values ranging from 1.5 to 0.0064μM. Among them, I (R = 2,6-diMe-4-CN) was regarded as the most excellent compound against WT HIV-1 (EC50 = 6.4 nM, SI = 2500). And also, it displayed potent activities against K103 N (EC50 = 0.077μM), Y181C (EC50 = 0.11μM), E138K (EC50 = 0.057μM), and moderate activity against double mutants RES056 (EC50 = 8.7μM). Moreover, the structure-activity relationships (SARs) were summarized, and the mol. docking was performed to investigate the binding mode of IPAPYs and HIV-1 reverse transcriptase. In the experimental materials used by the author, we found 2,4-Dichloropyrimidine(cas: 3934-20-1Recommanded Product: 3934-20-1)

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Organic chloride content in crude oil can be detected through specialized laboratory analysis. Care and attention are essential while sampling and testing.Recommanded Product: 3934-20-1

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia